Academic Journal
Comparative effects of local denosumab and recombinant human growth hormone on periodontal remodeling in experimental periodontitis.
| Τίτλος: | Comparative effects of local denosumab and recombinant human growth hormone on periodontal remodeling in experimental periodontitis. |
|---|---|
| Συγγραφείς: | Saad FA; Associate Professor of Oral Biology, Faculty of Dental Medicine, King Salman International University, South Sinai, Egypt. Electronic address: Fatma.adel@ksiu.edu.eg., El-Korashy SA; Professor of Inorganic Chemistry, Chemistry Department, Faculty of Science, Suez Canal University, Ismailia, Egypt. Electronic address: selko58@yahoo.com., Hamed AA; Associate professor of microbial chemistry, Microbial Chemistry Department, National Research Centre, Cairo, Egypt. Electronic address: ahmedshalbio@gmail.com., Robaian A; Associate professor and Consultant of restorative and implant dentistry, Conservative dental sciences department, College of dentistry, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia. Electronic address: ali.alQahtani@psau.edu.sa., Hassanein FEA; Assistant professor of Oral Medicine, Periodontology and Diagnosis, Faculty of Dental Medicine, King Salman International University, Egypt. Electronic address: fatma.hassanein@ksiu.edu.eg. |
| Πηγή: | Journal of stomatology, oral and maxillofacial surgery [J Stomatol Oral Maxillofac Surg] 2026 Oct; Vol. 127 (5), pp. 102955. Date of Electronic Publication: 2026 Aug 20. |
| Τύπος έκδοσης: | Journal Article; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Masson SAS Country of Publication: France NLM ID: 101701089 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-7855 (Electronic) Linking ISSN: 24687855 NLM ISO Abbreviation: J Stomatol Oral Maxillofac Surg Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Issy les Moulineaux Cedex : Elsevier Masson SAS, [2017]- |
| Ιατρικοί όροι (MeSH): | Periodontitis*/drug therapy , Periodontitis*/pathology , Periodontitis*/diagnostic imaging , Periodontitis*/microbiology , Bone Remodeling*/drug effects , Denosumab*/administration & dosage , Denosumab*/pharmacology , Human Growth Hormone*/administration & dosage , Human Growth Hormone*/pharmacology , Bone Density Conservation Agents*/administration & dosage , Bone Density Conservation Agents*/pharmacology, Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacology ; Animals ; Rabbits ; Male ; Humans ; Disease Models, Animal ; Cone-Beam Computed Tomography ; Random Allocation |
| Περίληψη: | Background: Periodontal regeneration remains challenging because conventional therapy does not predictably restore lost periodontal tissues. This study compared the periodontal remodeling responses associated with locally administered denosumab (DNS) and recombinant human growth hormone (rhGH) in experimental periodontitis. Materials and Methods: Twenty-four male New Zealand rabbits were randomly assigned to four groups: control, periodontitis (PDitis), PDitis treated with DNS, and PDitis treated with rhGH. Experimental periodontitis was induced by ligature placement and repeated inoculation with Porphyromonas gingivalis. Following disease induction, locally delivered DNS (3 mg) or rhGH (4 IU) gels were administered twice weekly for four weeks. Periodontal remodeling was evaluated using cone-beam computed tomography (CBCT), histological and histomorphometric analyses, and quantitative real-time polymerase chain reaction (qRT-PCR) assessment of bone remodeling-related genes. Results: Both DNS and rhGH improved periodontal healing compared with untreated periodontitis. DNS demonstrated greater preservation of alveolar bone height (facial bone height: 11.97 ± 0.05 mm vs. 9.96 ± 0.06 mm for rhGH and 9.00 ± 0.17 mm for PDitis; P = 0.004) and higher facial bone density (898.47 ± 9.95 vs. 708.34 ± 9.83 and 728.90 ± 6.08, respectively; P = 0.004). Histomorphometric analysis showed the greatest new bone formation in the rhGH group, with facial and lingual new bone fractions of 74.44 ± 16.80 % and 64.78 ± 6.38 %, respectively (P = 0.005 and P < 0.001). Both therapies significantly downregulated osteoclastogenesis-related gene expression, with DNS producing greater suppression of RANKL, NFATc1, ACP-5, and Ctsk than rhGH. Conclusions: Within the limitations of this experimental study, DNS and rhGH were associated with distinct periodontal remodeling phenotypes in experimental periodontitis. DNS predominantly demonstrated an anti-resorptive remodeling profile characterized by preservation of mineralized bone architecture, whereas rhGH promoted a more anabolic high-turnover remodeling response associated with active new bone formation. These findings support the translational potential of locally delivered biologically targeted therapies as adjunctive approaches for periodontal regeneration. (Copyright © 2026 Elsevier Masson SAS. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare no competing interests. |
| Contributed Indexing: | Keywords: Alveolar bone loss; Denosumab; Local drug delivery; Osteoclastogenesis; Periodontal regeneration; Periodontitis; Rabbit model; Recombinant human growth hormone |
| Substance Nomenclature: | 0 (Recombinant Proteins) 4EQZ6YO2HI (Denosumab) 12629-01-5 (Human Growth Hormone) 0 (Bone Density Conservation Agents) |
| Entry Date(s): | Date Created: 20260820 Date Completed: 20261005 Latest Revision: 20261005 |
| Update Code: | 20261006 |
| DOI: | 10.1016/j.jormas.2026.102955 |
| PMID: | 42624464 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2468-7855 |
|---|---|
| DOI: | 10.1016/j.jormas.2026.102955 |